| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Oncology and Clinical Neurosciences, University of Calgary, Alberta, Canada.
Address correspondence and reprint requests to Dr. V. Wee Yong, Professor, Departments of Oncology and Clinical Neurosciences, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada; e-mail: vyong{at}ucalgary.ca
Interferon-ß and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Notably, while both ultimately decrease CNS inflammation, they do so by very different mechanisms. Interferon-ß has potent activity at the blood-brain barrier and impairs the trafficking of inflammatory cells into the CNS. In contrast, GA has negligible effect at the blood-brain barrier, allowing GA-specific T helper 2 lymphocytes to enter the CNS to decrease inflammation through bystander suppression. Other differences are also emphasized. The presence of GA-reactive lymphocytes within the CNS parenchyma may have the additional benefit of conferring neuroprotection through protective autoimmunity.
This article has been cited by other articles:
|
|
 |
|
  D. Cadavid, L. J. Wolansky, J. Skurnick, J. Lincoln, J. Cheriyan, K. Szczepanowski, S. S. Kamin, A. R. Pachner, J. Halper, and S. D. Cook Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study Neurology, June 9, 2009; 72(23): 1976 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Bernal, B Elias, H. Hartung, and B. Kieseier Regulation of matrix metalloproteinases and their inhibitors by interferon-{beta}: a longitudinal study in multiple sclerosis patients Multiple Sclerosis, June 1, 2009; 15(6): 721 - 727. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Korporal, J. Haas, B. Balint, B. Fritzsching, A. Schwarz, S. Moeller, B. Fritz, E. Suri-Payer, and B. Wildemann Interferon Beta-Induced Restoration of Regulatory T-Cell Function in Multiple Sclerosis Is Prompted by an Increase in Newly Generated Naive Regulatory T Cells Arch Neurol, November 1, 2008; 65(11): 1434 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Sattler, S. K. Williams, C. Neusch, M. Otto, J. R. Pehlke, M. Bahr, and R. Diem Flupirtine as Neuroprotective Add-On Therapy in Autoimmune Optic Neuritis Am. J. Pathol., November 1, 2008; 173(5): 1496 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Miyazaki, K Iwabuchi, S Kikuchi, T Fukazawa, M Niino, M Hirotani, H Sasaki, and K Onoe Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1044 - 1055. [Abstract] [PDF]
|
|
|
|
|
|
J Kraus, K Voigt, A. Schuller, M Scholz, K. Kim, M Schilling, W. Schabitz, P Oschmann, and B Engelhardt Interferon-{beta} stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro Multiple Sclerosis, July 1, 2008; 14(6): 843 - 852. [Abstract] [PDF]
|
|
|
|
 |
|
 S. C. Satchell, O. Buchatska, S. B. Khan, G. Bhangal, C. H. Tasman, M. A. Saleem, D. P. Baker, R. R. Lobb, J. Smith, H. T. Cook, et al. Interferon-beta Reduces Proteinuria in Experimental Glomerulonephritis J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2875 - 2884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Waeckerle-Men, A. Starke, and R. P. Wuthrich PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1527 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Maier, A. V. Kuhnert, N. Taheri, M. B. Sattler, M. K. Storch, S. K. Williams, M. Bahr, and R. Diem Effects of Glatiramer Acetate and Interferon-{beta} on Neurodegeneration in a Model of Multiple Sclerosis: A Comparative Study Am. J. Pathol., October 1, 2006; 169(4): 1353 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Multiple Sclerosis, June 1, 2006; 12(3): 309 - 320. [Abstract] [PDF]
|
|
|
|
|
|
R P Lisak, J A Benjamins, B Bealmear, B Yao, S Land, L Nedelkoska, and D Skundric Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures Multiple Sclerosis, April 1, 2006; 12(2): 149 - 168. [Abstract] [PDF]
|
|
|
|
|
|
E. Gonzalez-Rey, A. Fernandez-Martin, A. Chorny, J. Martin, D. Pozo, D. Ganea, and M. Delgado Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis: Down-Regulation of Inflammatory and Autoimmune Responses Am. J. Pathol., April 1, 2006; 168(4): 1179 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, H.-P. Hartung, D. Ekstein, and O. Abramsky Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis Neurology, March 28, 2006; 66(6): 955 - 955. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rus, C. A. Pardo, L. Hu, E. Darrah, C. Cudrici, T. Niculescu, F. Niculescu, K. M. Mullen, R. Allie, L. Guo, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain PNAS, August 2, 2005; 102(31): 11094 - 11099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Blair, M. E. Pease, J. Hammond, D. Valenta, J. Kielczewski, H. Levkovitch-Verbin, and H. Quigley Effect of Glatiramer Acetate on Primary and Secondary Degeneration of Retinal Ganglion Cells in the Rat Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Fox Immunopathology of multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S3 - S7. [Abstract] [Full Text]
|
|
|
|
|
|
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520. [Abstract] [PDF]
|
|
|
|
|
|
B. C. Kieseier, J. J. Archelos, and H.-P. Hartung Different Effects of Simvastatin and Interferon Beta on the Proteolytic Activity of Matrix Metalloproteinases Arch Neurol, June 1, 2004; 61(6): 929 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo Brain, June 1, 2004; 127(6): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kim, I. Ifergan, J. P. Antel, R. Seguin, M. Duddy, Y. Lapierre, F. Jalili, and A. Bar-Or Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis J. Immunol., June 1, 2004; 172(11): 7144 - 7153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, June 1, 2004; 10(1_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, May 1, 2004; 10(3_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
